Positive clinical trial results often lead to an increase in the stock price of biopharmaceutical companies. The announcement of maintained or improved efficacy in patients dosed up to 14 weeks with ulixacaltamide, a drug being developed by Praxis Precision Medicines, Inc., is likely to be viewed positively by investors and could potentially lead to an increase in the company's stock price in the short term.